PCSA Processa Pharmaceuticals, Inc. Insider Trading

CFO Russell Skibsted buys 2,190 shares amid coordinated insider buying cluster; stock near 52-week lows.

Processa Pharmaceuticals' CFO Russell Skibsted is buying shares at depressed valuations—the stock is trading well below its annual highs after significant declines over recent months. What makes this noteworthy is that Skibsted's purchase is part of a broader cluster of three insiders buying within a two-week window, suggesting coordinated confidence rather than isolated portfolio activity. This is noteworthy given the company's challenged fundamentals: Processa is unprofitable with sharply declining revenues, and the CFO's purchase of over half his existing holdings represents a meaningful personal commitment at a time when the company needs to demonstrate operational stability. The question for investors is whether this cluster reflects insiders genuinely believing the stock is oversold at current levels, or whether they're simply averaging down in a struggling biotech.

Chief Strategy Officer at struggling biotech buys shares near 52-week lows amid severe revenue decline.

Lin Patrick, the Chief Business-Strategy Officer at Processa Pharmaceuticals, purchased over 1,500 shares at heavily depressed levels, adding roughly a third to his existing holdings. This is noteworthy timing: the stock is trading well below its recent highs after declining sharply, and the company's fundamentals show severe distress with collapsing revenue and substantial losses. An officer's purchase at depressed valuations could signal either genuine conviction that the market has oversold the company or a forced move to demonstrate confidence during a difficult period. What matters most is whether Patrick's insider knowledge—given his strategy role—suggests the company has stabilized or has genuine catalysts ahead. Without visibility into recent developments, this purchase at depressed levels could be either a courageous contrarian bet or a hollow confidence-building gesture amid ongoing deterioration.

CAO Guy Wendy buys 1,748 shares of struggling biotech PCSA at market lows, adding to holdings amid deep losses.

Chief Administrative Officer Guy Wendy purchased nearly 1,750 shares of Processa Pharmaceuticals at current market levels, representing a meaningful increase to his holdings and signaling confidence in the stock's long-term value. This is noteworthy because the purchase occurs while the company is unprofitable with substantial operating losses and minimal revenue, fundamentals that have deteriorated sharply year-over-year. The stock is trading well below its recent highs, suggesting Wendy sees asymmetric risk-reward at depressed valuations. As a C-suite officer with direct insight into company operations and strategy, his decision to deploy personal capital during a period of financial stress—rather than waiting for turnaround proof—suggests conviction that the business trajectory or assets have value not yet reflected in the market price.

PCSA Pres. R&D buys 1,706 shares at $2.69; stock now -78.7% from $11.97 52-week high; 5-insider cluster buy pattern.

Young David, President of Research & Development, purchased 1,706 shares at $2.69 on 2026-04-30, expanding his holdings by 14.1% to 13.8K shares. This transaction occurred within a cluster of 5 insider buys over the past 14 days, suggesting coordinated interest at depressed valuations. The stock has collapsed -78.7% from its $11.97 52-week high and now trades at $2.55, -2.0% over 30 days and -15.0% over 90 days. Critically, Young's cross-ticker track record shows exceptional timing: 5 prior buys with avg 90d return +1765.7% and a 100% win rate, and at PCSA specifically, his prior 3 measurable buys were uniformly well-timed at the 90-day mark, posting +2212.9%, +2187.0%, and +1614.7% returns respectively. However, current fundamentals are severely distressed: the company reported $0.00 revenue in the latest quarter, a $-3.4M net loss, and a $7.0M market cap. The clustering activity combined with Young's proven track record of identifying value inflection points merits close monitoring, but the profound revenue collapse raises questions about whether historical patterns remain predictive in a company facing potential existential challenges.

CDO bought 1,986 shares at $2.69; 36.0% increase to 7.5K-share position. Stock down -78.7% from high, company unprofitable.

Chief Development Officer Sian purchased 1,986 shares of Processa Pharmaceuticals at $2.69 on 2026-04-30, increasing holdings by 36.0% to 7.5K shares total—a material position increase. The timing coincides with a cluster of 5 other insiders buying within the past 14 days, suggesting coordinated activity during a period of depressed valuation; the stock trades at -78.7% from its 52-week high of $11.97 and currently sits at $2.55, down 15.0% over 90 days. However, the company's fundamentals remain deeply challenged: revenue is $0.00 (latest quarter), net income is $-3.4M, and the market cap is only $7.0M—reflecting a pre-revenue biotech with significant cash burn. Sian's cross-ticker track record shows 2 prior buys averaging +6.5% 30-day returns, but at this specific ticker, timing outcomes remain inconclusive: his prior PCSA buy on 2026-03-31 shows +6.5% 30-day return but 90-day outcome is not yet measurable. The cluster pattern and substantial position increase warrant attention to whether cash reserves and runway support continued operations.

CEO George K Ng bought 2,034 shares at $2.69 on 2026-04-30; 51.1% increase in holdings amid cluster buy pattern and extreme valuation pressures ($7.0M market cap, -78.7% from 52-week high).

CEO George K Ng purchased 2,034 shares of PCSA at $2.69, increasing his holdings by 51.1% from 3,979 to 6,013 shares. This follows a cluster buy pattern: 5 other insiders also bought within the past 14 days, suggesting coordinated board or management-level confidence signals. His same-ticker trade history at PCSA shows strong execution: his prior buy on 2025-01-27 returned +643.6% over 90 days, and his 2024-01-30 buy returned +1844.4% over 90 days—a 2 of 2 well-timed rate at the 90-day mark. However, the current fundamentals are severe: the company reported $0.00 revenue in the latest quarter, negative net income of $-3,436,573.00, and a $7.0M market cap. The stock trades -78.7% from its 52-week high of $11.97 and has declined -15.0% over the past 90 days. The cluster buy during an extreme valuation trough combined with CEO scale-up (51.1% portfolio expansion) and his demonstrated ability to identify turning points at this ticker warrants close monitoring, though the company's lack of revenue and persistent unprofitability pose material execution risk.

PCSA President of R&D buys 1,545 shares at $2.97; 3 of 3 prior buys at this ticker hit +90d gains; 5 other insiders bought within 14 days.

Young David's purchase of 1,545 shares represents a 14.6% increase in his PCSA holdings, adding to a pattern of buying activity: he repurchased shares on 2026-03-31 (outcome not yet measurable) and achieved 90-day returns of +1614.7% and +2212.9% on his two prior 2024–2025 buys at this ticker. His same-ticker timing pattern shows 3 of 3 prior buys were well-timed at the 90-day mark. Concurrently, 5 other insiders have bought within the past 14 days, forming a cluster buy pattern. However, the company remains unprofitable (net income of $-3,436,573.00 for the latest full fiscal year), trades at a current price of $3.10 that is -74.1% from its 52-week high of $11.97, and generated $0.00 revenue in the latest quarter, presenting substantial financial headwinds that contextualize the multiple insider purchases.

CEO George K Ng bought 1,843 shares of PCSA at $2.97 on 2026-04-15; stock -74.1% from 52-week high, cluster buy by 5 other insiders within 14 days.

CEO Ng purchased 1,843 shares at $2.97, increasing his holdings by 50.5% to 5,492 shares. The purchase occurs at a steep discount to the 52-week high of $11.97, with the stock currently trading at $3.10, down 12.4% over 90 days. His prior two purchases at PCSA (2025-01-27 and 2024-01-30) both delivered strong 90-day returns of +643.6% and +1844.4% respectively, establishing a 2-for-2 well-timed buying pattern at this ticker. Critically, this purchase is part of a broader insider cluster: 5 other insiders bought within the past 14 days. However, this must be contextualized against fundamentals—the company generated $0.00 in revenue during the latest quarter with a net loss of $-3,436,573.00 and a market cap of only $8,246,120.90. The coordinated buying activity by multiple insiders during a severe drawdown warrants scrutiny, but the company's zero revenue and significant unprofitability constrain the predictive power of insider transactions alone.

CFO Russell Skibsted buys 1,984 shares of PCSA at $2.97; stock down -74.1% from 52-week high of $11.97

Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, purchased 1,984 shares on 2026-04-15 at $2.97, increasing his holdings by 85.4% to 4,308 shares post-transaction. The purchase comes while the stock trades at $3.10, down -74.1% from its 52-week high of $11.97, and the company reported zero revenue and a net loss of -$3,436,573.00 in its latest quarter. A cluster pattern is present, with 5 other insiders also buying within the past 14 days. However, the CFO's cross-ticker track record shows only 1 prior buy with no measurable outcomes yet, providing limited context for assessing his historical execution at this ticker.

CAO Guy Wendy buys 1,583 shares of PCSA at $2.97; 5 other insiders also bought in past 14 days (cluster pattern).

Guy Wendy, Chief Administrative Officer, purchased 1,583 shares at $2.97 on 2026-04-15, increasing her holdings by +50.9% to 4,693 shares. This transaction is part of a cluster pattern in which 5 other insiders also bought within the past 14 days, suggesting coordinated confidence at current valuations. However, context is mixed: the stock trades at $3.10 (current price), down -74.1% from its 52-week high of $11.97, and the company posted zero revenue in the latest quarter with a net loss of $-3.4M and a market cap of $8.2M. While multiple insider purchases can indicate management belief in value, the severe valuation pressure and operational losses in an unprofitable biotech warrant careful scrutiny of the motivations underlying this cluster activity.